Incyte Corp (NAS:INCY)
$ 57.05 -0.55 (-0.95%) Market Cap: 12.83 Bil Enterprise Value: 9.01 Bil PE Ratio: 17.29 PB Ratio: 2.37 GF Score: 88/100

Incyte Corp at Cowen and Company Health Care Conference Transcript

Mar 11, 2019 / 04:00PM GMT
Release Date Price: $84.17 (+2.50%)
Unidentified Analyst

Okay. Welcome back. Next up, we have Incyte and CEO, Hervé Hoppenot. Get the mic back on.

HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO

© -

I'm here, yes.

Unidentified Analyst

So I think we'll start out. Hervé will just give a couple minute just brief kind of status of Incyte, get everybody on the same page, and then we'll jump into some questions. Okay?

HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO

© -

Okay, and also, I mean, the 5 minutes where to think about Incyte today is, first, the discovery process is working at Incyte. I think it's important because we have -- we are one of these company where we have been able to integrate the full chain from discovery, chemistry, biology, clinical development, where we have established a platform that goes -- now works in the U.S, Europe and Japan and, obviously, commercial teams that are in U.S. and Europe operational and in Japan, when we get the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot